SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-22-009116
Filing Date
2022-03-08
Accepted
2022-03-08 16:40:44
Documents
14
Period of Report
2022-03-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K evok-8k_20220308.htm   iXBRL 8-K 39651
2 EX-99.1 evok-ex991_6.htm EX-99.1 271909
3 GRAPHIC gq51ihp41cdo000001.jpg GRAPHIC 24471
  Complete submission text file 0001564590-22-009116.txt   491002

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA evok-20220308.xsd EX-101.SCH 5705
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE evok-20220308_lab.xml EX-101.LAB 19431
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE evok-20220308_pre.xml EX-101.PRE 11591
8 EXTRACTED XBRL INSTANCE DOCUMENT evok-8k_20220308_htm.xml XML 3552
Mailing Address 420 STEVENS AVENUE SUITE 370 SOLANA BEACH CA 92075
Business Address 420 STEVENS AVENUE SUITE 370 SOLANA BEACH CA 92075 858-345-1494
Evoke Pharma Inc (Filer) CIK: 0001403708 (see all company filings)

IRS No.: 208447886 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36075 | Film No.: 22722264
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences